Local and Systemic Antitumor Effects of Photo‐activatable Paclitaxel Prodrug on Rat Breast Tumor Models
Abstract
We demonstrated that a large primary and a small untreated distant breast cancer could be controlled by local treatment with our light‐activatable paclitaxel (PTX) prodrug. We hypothesized that the treated tumor would be damaged by the combinational effects of photodynamic therapy (PDT) and locally released PTX and that the distant tumor would be suppressed by systemic antitumor effects. Syngeneic rat breast cancer models (single‐ and two‐tumor models) were established on Fischer 344 rats by subcutaneous injection of MAT B III cells. The rats were injected with PTX prodrug (dose: 1 umole kg−1, i.v.), and tumors were treated with illumination using a 690‐nm laser (75 or 140 mW cm−1 for 30 min, cylindrical light diffuser, drug‐light interval [DLI] 9 h). Larger tumors (~16 mm) were effectively ablated (100%) without recurrence for >90 days. All cured rats rejected rechallenged tumor for up to 12 months. In the two‐tumor model, the treatment of the local large tumor (~16 mm) also cured the untreated tumor (4–6 mm) through adaptive immune activation. This is our first demonstration that local treatment with our PTX prodrug produces systemic antitumor effects. Further investigations are warranted to understand mechanisms and optimal conditions to achieve clinically translatable systemic antitumor effects.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 09, 2020
- Source ID
- 10.1111/php.13202
Entities
People
- Bharathiraja Subramaniyan
- Cody J. Peer
- Jessica Kindrick
- Luong N. Nguyen
- Mengjie Li
- Pallavi Rajaputra
- Sukyung Woo
- William Douglas Figg, Sr.
- Youngjae You
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- National Institute of General Medical Sciences
- University at Buffalo
- University of Oklahoma
- University of Oklahoma Health Sciences Center